CIA astraZenacas research and development office is paying a research and consulting firm $3,876,632 to hire a former Astra Zeneca researcher for a $2 million research grant to build a “psychoanalytic” astrocyte brain, according to documents obtained by Newsweek.
The agency has long had a long-standing relationship with AstreaZeneca, which is based in the United Kingdom.
According to a 2013 profile in Forbes magazine, Astra was the subject of a $3 million investigation into whether the company was selling its products to Iran.
A spokesman for the CIA told Newsweek the agency does not comment on ongoing investigations.
The CIA has long relied on Astrea for research and has paid the company more than $5 million to fund its research projects, according the profile.
The Astra project has been a contentious issue since its inception in 2000, when the agency sued Astrea to prevent the company from making a vaccine for the hepatitis C virus.
The FDA ordered Astra to stop the use of its vaccine in 2015, citing safety concerns.
Astra refused to comply, and in 2018 the FDA sued the company to force it to stop its use of the vaccine.
In a letter dated August 27, the FDA wrote that “the FDA cannot accept Astra’s assertion that it has not been a party to or involved in any activity relating to the hepatitis vaccine, including the Astra vaccine, and that its vaccine does not contain any material or potential vaccine contaminants.”
Astra responded in a court filing on October 16, 2018, saying the FDA’s actions are “misleading” and that “we have complied with FDA’s request and remain in compliance with FDA requests in all other respects.”
The agency did not respond to Newsweek’s request for comment on this story.
Newsweek obtained documents from Astra from the Office of the Inspector General of the CIA.
The documents show that Astra hired a former senior executive at Astra for $3 to $4 million.
In addition to the Astrea contract, the CIA is paying $300,000 to the company’s former scientific director for consulting services.
In December 2018, the agency announced that it had terminated its contract with Astara for vaccine development and production of a hepatitis vaccine.
The contract had been with Astira since 2011, but it was canceled in January 2017.
The new contract with the company, which began in February 2018, is for $4.6 million, according a September 2018 memo sent to the CIA from the agency’s Office of Inspector General.
Astara said in a statement that it is continuing to support the CIA in its research and innovation efforts.
“The Astra group has always had a strong relationship with the CIA,” said the statement, which was issued by the company.
“As we have done with many other agencies, we continue to work with the Office and the CIA on the development and development of vaccines and related products.”
Astrea declined to comment for this story, citing a confidentiality agreement.
The company also declined to answer questions about its relationship with NASA.
According the CIA’s contract with NASA, Astrea “has a contract with its subcontractor to provide technical assistance in the development of a ‘psycho-analytic’ astro-cyte system that will be used to analyze the brain of a human subject with and without Alzheimer’s disease.”
Astana also hired a psychologist and neuroscientist to “conduct neuroimaging studies of patients in their homes” in the future, according an October 2017 contract with “NASA.”
“Astra has had a significant involvement in the design, engineering and production and delivery of its products and services to NASA,” the company said in the statement.
“These services include product development, engineering, testing, manufacturing and sales.”
The CIA contract with this company was terminated in January 2018.
According a September 2017 memo sent by the CIA to Astra, Astara has continued to use Astra as a supplier of vaccine development services and “as a supplier for the development, production and distribution of its vaccines.”
The document states that Astana “continues to provide Astra with a high level of support in developing vaccine products and providing them to other agencies.”
According to documents in the CIA contract, Asta’s contract included “specialized technical support” for “program management, risk management, and technical support, as well as for data and research support, development and implementation of product development plans, training and quality assurance, and marketing and distribution activities.”
The Astrea project is one of several Astra-related projects the CIA has been involved in since the mid-2000s.
According as an August 2018 letter from the CIA, “Astrea’s participation in a number of U.S. government programs was critical to the Agency’s understanding of its research, and helped to establish a successful relationship with U. S. government.”
The letter said that